Aim: c-Met kinase deregulation is strongly associated with the formation, progression and dissemination of human cancers. In this study we identified Yhhu3813 as a small-molecule inhibitor of c-Met kinase and characterized its antitumor properties both in vitro and in vivo. Methods: The activities of different kinases were measured using ELISA assays and signaling proteins in the cells were detected with Western blotting. Cell proliferation was assessed using SRB or MTT assay in twenty human cell lines and cell cycle distribution was determined with flow cytometry. Transwell-based assay was used to evaluate cell migration and invasion. Cell invasive growth was detected by a morphogenesis assay. c-Met overactivated human NSCLC cell line EBC-1 xenografts were used to evaluate the in vivo anti-tumor efficacy. , qd, for 2 weeks) dose-dependently suppressed the tumor growth, which was correlated with a reduction in the intratumoral proliferation index and c-Met signaling. Conclusion: Yhhu3813 is a potent selective inhibitor of c-Met that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells in vitro and in vivo.
Introduction c-Met is a prototype member of a subfamily of heterodimeric receptor tyrosine kinases (RTKs). The mature form of c-Met is composed of an extracellular alpha-chain and a transmembrane beta-chain linked by a disulfide bond. Hepatocyte growth factor (HGF) is the only known high-affinity ligand of c-Met receptor [1] . The physiological functions of the c-Met pathway are restricted to mammalian development and tissue homeostasis. Aberrant c-Met activation has frequently been observed in a variety of human solid tumors and hematologic malignancies. c-Met was originally identified as the protein product of a translocated promoter region (TPR)-MET oncogene in an in vitro-transformed human osteosarcoma cell line. TPR-MET rearrangement represents an oncogenic form of the c-Met receptor and has been detected in human gastric cancers. In addition to genetic translocation, MET gene amplification or overexpression or an elevation of the HGF level can all lead to c-Met overactivation [1] . Indeed, MET amplification and/ www.nature.com/aps He CX et al Acta Pharmacologica Sinica npg or overexpression have been reported in various cancer types, including brain, gastric, colorectal, and lung cancers, whereas HGF elevation occurs in most human cancers [2] [3] [4] [5] [6] [7] [8] . Importantly, both c-Met and HGF elevation have been associated with poor clinical outcomes [7, [9] [10] [11] [12] . In addition, the propagation of the c-Met-dependent invasive growth process has been shown to be a general and important feature of highly aggressive tumors [1, 13, 14] . All these lines of evidence render the c-Met axis an attractive target for cancer therapy and inspire increasing efforts into the discovery of c-Met inhibitors.
Despite vigorous activity in the development of c-Met inhibitors, no c-Met inhibitor or c-Met pathway antagonist has yet been approved for clinical use. Notably, most c-Met inhibitors currently undergoing clinical trials are multi-target inhibitors, with the unwanted inhibition of additional kinases often accounting for the observed undesirable toxicity [8] . Accordingly, highly selective c-Met inhibitors, which largely avoid off-target toxicities at therapeutic doses, currently represent the main direction for the development of c-Met inhibitors.
Here, we report a novel and highly selective c-Met inhibitor, Yhhu3813, which was obtained through a c-Met-targeted small-molecule screening. We show that Yhhu3813 effectively inhibited overactivated c-Met signaling across the oncogenic forms, including MET amplification, MET chromosomal rearrangement (TPR-MET), and HGF elevation. In turn, Yhhu3813 suppressed the c-Met-dependent oncogenic phenotypes of tumor cells and showed a marked antitumor efficacy in c-Metdriven tumor models. Our results suggest that, by targeting c-Met, Yhhu3813 is a potential candidate for anticancer drug development.
Materials and methods

Compound
Yhhu3813[6-(6-fluoro-1H-indol-1-yl)-2-(2-((7-(3-(4-methylpiperazin-1-yl)propoxy)quinolin-4-yl)oxy)ethyl)pyridazin-3(2H)-one] was synthesized at Prof You-hong HU's Laboratory in Shanghai Institute of Materia Medica. The purity of Yhhu3813 was 99%.
ELISA kinase assay
The effects of Yhhu3813 on the activities of various tyrosine kinases were determined using enzyme-linked immunosorbent assays (ELISAs) with purified recombinant proteins. Briefly, 20 μg/mL poly (Glu,Tyr) 4:1 (Sigma, St Louis, MO, USA) was pre-coated in 96-well plates as a substrate. A 50-μL aliquot of 10 μmol/L ATP solution diluted in kinase reaction buffer (50 mmol/L HEPES [pH 7.4], 50 mmol/L MgCl 2 , 0.5 mmol/L MnCl 2 , 0.2 mmol/L Na 3 VO 4 , and 1 mmol/L DTT) was added to each well; 1 μL of various concentrations of Yhhu3813 diluted in 1% DMSO (v/v) (Sigma, St Louis, MO, USA) were then added to each reaction well. DMSO (1%, v/v) was used as the negative control. The kinase reaction was initiated by the addition of purified tyrosine kinase proteins diluted in 49 μL of kinase reaction buffer. After incubation for 60 min at 37 °C, the plate was washed three times with phosphate-buffered saline (PBS) containing 0.1% Tween 20 (T-PBS).
Anti-phosphotyrosine (PY99) antibody (100 μL; 1:500, diluted in 5 mg/mL BSA T-PBS) was then added. After a 30-min incubation at 37 °C, the plate was washed three times, and 100 μL horseradish peroxidase-conjugated goat anti-mouse IgG (1:2000, diluted in 5 mg/mL BSA T-PBS) was added. The plate was then incubated at 37 °C for 30 min and washed 3 times. A 100-μL aliquot of a solution containing 0.03% H 2 O 2 and 2 mg/mL o-phenylenediamine in 0.1 mol/L citrate buffer (pH 5.5) was added. The reaction was terminated by the addition of 50 μL of 2 mol/L H 2 SO 4 as the color changed, and the plate was analyzed using a multi-well spectrophotometer (SpectraMAX 190, from Molecular Devices, Palo Alto, CA, USA) at 490 nm. The inhibition rate (%) was calculated using Western blot analysis NCI-H441 and MDCK cells were serum-starved for 24 h, treated with the indicated dose of Yhhu3813 for 2 h at 37 °C, stimulated with HGF (100 ng/mL, PeproTech, Rocky Hill, NJ, USA) for 15 min, and then lysed in 1×sodium dodecyl sulfate (SDS) sample buffer. EBC-1, MKN-45, and BaF3/TPR-Met cells were treated with the indicated dose of Yhhu3813 for 2 h at 37 °C and then lysed in 1×SDS sample buffer. The cell lysates were subsequently resolved by 10% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with the appropriate primary antibodies [c-Met and cyclin E (Santa Cruz, CA, USA), phospho-c-Met, phospho-ERK1/2, ERK1/2, phospho-AKT, AKT, and Cyclin D1 (all from Cell Signaling Technology, Beverly, MA, USA), and GAPDH (KangChen Biotech, Shanghai, China)] and then with horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG. The immunoreactive proteins were detected using an enhanced chemiluminescence detection reagent (Thermo Fisher Scientific, Rockford, IL, USA). Cell proliferation assay Cells were seeded in 96-well tissue culture plates. On the next day, the cells were exposed to various concentrations of compounds and further cultured for 72 h. Cell proliferation was then determined using sulforhodamine B (SRB, from Sigma-Aldrich, St Louis, MO, USA) or the thiazolyl blue tetrazolium bromide (MTT, from Sigma-Aldrich, St Louis, MO, USA) assay. The IC 50 values were calculated by concentrationresponse curve fitting using the four-parameter method.
Cell cycle distribution assay EBC-1 or MKN45 cells (1×10 5 ) were seeded in 6-well plates overnight and treated with different concentrations of Yhhu3813 on the following day. After 24 h, the cells were collected by EDTA-free trypsinization, centrifuged at 1000×g, and fixed in 70% ethanol at -20 °C for 1 h. The cells were then centrifuged at 2000×g, resuspended in 500 μL PBS containing 20 ng/mL RNase and 10 ng/mL propidium iodide, incubated in the dark for 30 min at room temperature, and analyzed using flow cytometry (FACsCalibur, from BD bioscience, San Jose, CA, USA). The data were analyzed using Modifit LT.
Migration assay and invasion assay
For the migration assay, NCI-H441 cells suspended in serumfree medium (1.5×10 5 cells per well) were seeded in 24-well Transwell plates (pore size, 8 μm; Corning). The bottom chambers were filled with serum-free medium supplemented with HGF (100 ng/mL), and 125 nmol/L, 250 nmol/L, and 500 nmol/L of Yhhu3813 was added to both sides of the membrane. The cultures were maintained for 24 h, followed by the removal of non-motile cells at the top of the filter using a cotton swab. The migrating cells were fixed in paraformaldehyde (4%) and stained with crystal violet (0.1%) for 15 min at room temperature. The dye that was taken up by the cells bound to the membrane was released by the addition of 100 µL 10% acetic acid, and the absorbance of the resulting solution was measured at 595 nm using a multiwell spectrophotometer (Spetra-MAX 190, from Molecular Devices, Palo Alto, CA, USA). The assay was performed in triplicate.
For the invasion assay, NCI-H441 cells were cultured in the top chambers containing Matrigel-coated membrane inserts (Matrigel, BD). The ensuing procedure was identical to the migration assay. The assay was performed in triplicate. Images were obtained using an Olympus BX51 microscope.
Cell-scatter assay MDCK cells (1.5×10 3 cells per well) were plated in 96-well plates and grown overnight. Increasing concentrations of Yhhu3813 and HGF (100 ng/mL) were added to the appropriate wells, and the plates were incubated at 37 °C and 5% CO 2 for 24 h. The cells were fixed with 4% paraformaldehyde for 15 min at room temperature and then stained with 0.2% crystal violet, washed with water, and dried. Images were obtained using an Olympus IX51 microscope.
Cell branching morphogenesis assay MDCK cells at a density of 2×10
4 cells/mL in DMEM medium were mixed with an equal volume of collagen I solution and plated at 0.1 mL/well in a 96-well culture plate. After incubation for 45 min at 37 °C and 5% CO 2 to allow the collagen to gel, HGF (100 ng/mL) with or without Yhhu3813 at various concentrations dissolved in 100 μL of growth medium was added to each well. The medium was replaced with fresh growth medium every 2 d. Images were obtained using an Olympus IX51 microscope after 5 d.
In vivo anti-tumor activity assay Female nude mice (4-6 weeks) were housed at five or six mice per cage in a specific pathogen-free room with a 12-h light/ dark schedule at 25±1 °C; the animals were fed an autoclaved chow diet and water ad libitum. All the animal experiments were performed according to the institutional ethical guidelines of animal care.
EBC-1 cells at a density of (5-10)×10 6 in 200 μL were first implanted sc into the right flank of each mouse and then allowed to grow to 700-800 mm 3 , which was defined as a welldeveloped tumor. The well-developed tumors were cut into 1-mm 3 fragments and transplanted sc into the right flank of nude mice using a trocar. When the tumor volume reached 100-150 mm 3 , the mice were randomly assigned into control and treatment groups (n=4 per group). The control groups were given vehicle alone, and the treatment groups received Yhhu3813 at the indicated doses via oral administration once daily for 2 weeks. The sizes of the tumors were measured twice per week using microcalipers. The tumor volume (TV) was calculated as follows: TV=(length×width 2 )/2. The tumor volume shown was obtained on the indicated days as the median tumor volume±SEM for indicated groups of mice. The percent (%) inhibition values were measured on the final day of the study for the drug-treated compared with the vehicletreated mice and were calculated as 100%×{1-[(treated final day-treated d 0)/(control final day-control day 0)]}. Significant differences between the treated versus the control groups (P≤0.05) were determined using Student's t test.
Immunohistochemistry assay
The tumor specimens were fixed in 10% buffered formalin for over 24 h before being transferred to 70% ethanol. The tumor samples were subsequently paraffin-embedded, and sections were cut and baked onto microscope slides. The slides were incubated with primary antibodies (Ki67 antibody purchased from Epitomics, Burlingame, CA, USA) and then secondary antibodies and visualized using a colorimetric method (DAB kit; ZSGB-Bio, Beijing, China). Images were obtained using an Olympus BX51 microscope.
Statistical analysis
Data from the in vitro assays are presented as the mean±SD. While in the in vivo assay, data are presented as the 
Results
Yhhu3813 is a selective, ATP-competitive inhibitor of c-Met
In an enzymatic screen designed to identify c-Met inhibitors, Yhhu3813 was distinguished for its remarkable potency against recombinant human c-Met kinase, with an average IC 50 value of 2.4 nmol/L. Accordingly, we were prompted to investigate whether this potency was specifically against c-Met. Thus, the activity of Yhhu3813 was evaluated against a panel of kinases (Table 1 ). In contrast to its high potency against c-Met, Yhhu3813 barely inhibited the kinase activity of 15 tested tyrosine kinases, including c-Met family member Ron and highly homologous kinase Tyro3 (IC 50 >1 μmol/L), indicating that Yhhu3813 is a selective c-Met inhibitor.
Binding to the ATP pocket and in turn blocking the kinase activity represents the most common mechanism of smallmolecule kinase inhibitors. To examine whether Yhhu3813 functions in this manner, we evaluated the inhibitory potency of Yhhu3813 on c-Met activity using a competitive assay by introducing increasing concentrations of ATP (Figure 1) . A Lineweaver-Burk plot for c-Met inhibition by Yhhu3813 with respect to the ATP concentration showed all the curves intersecting the y-intercept at zero, which indicates a competitive mechanism of inhibition. Collectively, Yhhu3813 acts as a potent, selective and ATP-competitive inhibitor of c-Met. Yhhu3813 impairs c-Met-driven cell proliferation Activated c-Met is known to trigger cancer cell proliferation [15] . Therefore, we next assessed the effect of Yhhu3813 on cell proliferation in a broad panel of human cancer cell lines harboring different backgrounds of c-Met expression/activation. The (Table 2 ). These data indicate Figure 4E ). In addition, no obvious sub-G 1 cell population was observed after Yhhu3813 treatment ( Figure 4A , 4B), largely excluding the occurrence of Yhhu3813-induced apoptosis. We therefore concluded that Yhhu3813 inhibits c-Met-mediated cell proliferation by inducing G 1 /S arrest.
Yhhu3813 effectively inhibits c-Met activation and signaling in cancer cells
Yhhu3813 inhibits c-Met-dependent cell migration, invasion, and scattering In addition to the modulation of cell proliferation, activation of the HGF/c-Met axis promotes cell migration and invasion, which contribute to the metastatic characteristics of malignant cells [16] . Thus, we next evaluated the impact of Yhhu3813 in www.nature.com/aps He CX et al Acta Pharmacologica Sinica npg this regard. NCI-H441 cells were treated with HGF in the presence of Yhhu3813, and the migratory and invasive abilities were determined using Transwell-based migration and invasion assays. Our results indicated that Yhhu3813 strongly suppresses HGF-induced cell migration and invasion in a dose-dependent manner and that a dose of 500 nmol/L is sufficient to block the movement of most NCI-H441 cells ( Figure  5A-5D) . Activated HGF/c-Met signaling is also known to promote the cell scattering that stimulates cells to abandon their original environment [17] [18] [19] , a hallmark of cancer invasiveness and metastasis. It has been well documented that MDCK cells, which normally grow in clusters, exhibit a disruption and scattering of the cell colonies upon HGF stimulation. We thus determined the effect of Yhhu3813 on cell scattering behavior using MDCK cells stimulated by HGF. As shown in Figure  5E , Yhhu3813 treatment reduced the HGF-induced cell scattering of MDCK cells in a dose-dependent manner, completely blocking cell spreading at the dose of 500 nmol/L.
Together, our data suggest that Yhhu3813 significantly impairs the cell motility and invasiveness mediated by the HGF/c-Met axis.
Yhhu3813 suppresses c-Met-mediated invasive growth c-Met activation in epithelial cells is known to induce a series of biological responses that collectively give rise to a unique multistep program known as invasive growth [1, 20, 21] . Indeed, c-Met aberration enables cancer cells to commandeer the ability of normal cells in this regard, enabling cancer persistence and metastasis [21] [22] [23] [24] . In vitro, this morphogenetic program was recapitulated by stimulating cultured MDCK epithelial cells in suspension in a three-dimensional extracellular matrix (collagen) with HGF. We then evaluated the efficacy of Yhhu3813 to inhibit this phe- Figure 7A ). We also evaluated the intratumoral Ki67 proliferation index and observed a significant decrease in the group administered 100 mg/kg Yhhu3813 ( Figure 7B ). In agreement with the suppressed tumor growth, a marked reduction in the intratumoral phosphorylation of c-Met and downstream Akt and Erk was observed at 2 h after oral administration of 100 mg/kg Yhhu3813 ( Figure 7C ). Taken together, Yhhu3813 showed a robust anti-tumor efficacy that was correlated with the inhibition of c-Met-mediated signaling in a c-Met-dependent tumor model.
Discussion
The c-Met pathway is frequently deregulated in a wide variety of human cancers and plays critical roles in cancer formation, progression, and dissemination, in addition to the resistance to approved therapies [1] . Therefore, the inhibition of increased c-Met signaling could have a significant potential in the treatment of human cancers in which the c-Met pathway is aberrantly activated. In fact, recent clinical trials of c-Met pathway-targeted agents have yielded convincing evidence to support the potential utility of this class of agents in treating various human cancers [25] [26] [27] [28] . In this study, we assessed the antitumor efficacy of Yhhu3813, an orally bioavailable, selective, small-molecule inhibitor of the catalytic activity of the c-Met kinase. Yhhu3813 potently inhibited c-Met phosphorylation and the activation of its key downstream effectors in c-Met-dependent tumor cell lines. As a result, Yhhu3813 potently inhibited c-Met-mediated tumor cell proliferation, migration, and invasion. Consistently, Yhhu3813 inhibited the c-Met-mediated complex morphogenetic program of invasive growth upon HGF stimulation. Furthermore, the oral dosing of Yhhu3813 resulted in a marked antitumor activity in a c-Met-driven EBC-1 tumor model.
An interesting feature of Yhhu3813 is its selectivity against c-Met. Yhhu3813 presented IC 50 values for c-Met in the nanomolar range in a kinase assay and showed at least more than 400-fold selectivity over a panel of 15 human kinases, including c-Met family member Ron and the highly homologous kinase Tyro3. Consistently, the anti-proliferative activity of Yhhu3813 was more than 40-fold more potent for c-Metaddicted cells in contrast to a panel of tumor cell lines with low c-Met expression and activity. It is worth noting that most of the reported c-Met kinase inhibitors being clinically evaluated are not very selective for c-Met and exhibit activities against multiple kinases, often resulting in unwanted off-target toxicity. By lacking the confounding issue of off-target kinase inhibition, Yhhu3813 might overcome the aforementioned limitations of other c-Met inhibitors and could specifically achieve the therapeutic potential of c-Met inhibition alone. In addition, the feature of high selectivity renders Yhhu3813 suitable for use as a tool inhibitor in preclinical models to dissect the role of c-Met catalytic activity in cancer progression.
